Grewal Harpreet, an insider at Penumbra Inc (PEN), sold 8,416 shares of the company on December 1, 2025, at a price of $292.98 per share, totaling approximately $2.47 million. Following this transaction, Harpreet retains 8,416 shares in the company.
Penumbra, headquartered in Alameda, California, is a leader in the health care sector, specializing in thrombectomy products designed to remove blood clots. With a market cap of $11.5 billion and a P/E ratio of 70.31, the company has positioned itself as a key player in treating conditions like Pulmonary Embolism and Acute Limb Ischemia.
Insider selling can occur for various reasons, including diversification or personal financial needs. While such transactions warrant attention, they do not inherently signal negative views on the company. Investors should consider insider activity as one of many factors when evaluating a stock's potential.
Insider transactions are reported to the SEC, providing transparency into the actions of company executives. However, focusing on isolated transactions may not give a complete picture. Observing patterns across multiple insiders can offer deeper insights into a company's trajectory.
Looking ahead, Penumbra is set to report its earnings on April 21, 2026, with expectations of an EPS of $1.10 and revenue of $373.7 million, followed by another report on July 27, 2026, where an EPS of $1.21 and revenue of $391.3 million is anticipated.